Cargando…
Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
Type 1 diabetes (T1D) is a T cell–mediated autoimmune disease, although B cells also play an important role in T1D development. Both T cell– and B cell–directed immunotherapies have shown efficacy in the prevention and reversal of T1D. However, whether the combined strategy of targeting both T and B...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717853/ https://www.ncbi.nlm.nih.gov/pubmed/23447122 http://dx.doi.org/10.2337/db12-1175 |
_version_ | 1782277740492226560 |
---|---|
author | Hu, Changyun Ding, Heyuan Zhang, Xiaojun Wong, F. Susan Wen, Li |
author_facet | Hu, Changyun Ding, Heyuan Zhang, Xiaojun Wong, F. Susan Wen, Li |
author_sort | Hu, Changyun |
collection | PubMed |
description | Type 1 diabetes (T1D) is a T cell–mediated autoimmune disease, although B cells also play an important role in T1D development. Both T cell– and B cell–directed immunotherapies have shown efficacy in the prevention and reversal of T1D. However, whether the combined strategy of targeting both T and B cells could further improve therapeutic efficacy remains to be explored. We show that combined treatment with intravenous antihuman CD20 (hCD20) and oral anti-CD3 significantly delays diabetes development in prediabetic hCD20 transgenic NOD mice. More importantly, the combined treatment reverses diabetes in >60% of mice newly diagnosed with diabetes. Further mechanistic studies demonstrated that the addition of oral anti-CD3 to the B-cell depletion therapy synergistically enhances the suppressive function of regulatory T cells. Of note, the oral anti-CD3 treatment induced a fraction of interleukin (IL)-10–producing CD4 T cells in the small intestine through IL-10– and IL-27–producing dendritic cells. Thus, the findings demonstrate that combining anti-CD20 and oral anti-CD3 is superior to anti-CD20 monotherapy for restoring normoglycemia in diabetic NOD mice, providing important preclinical evidence for the optimization of B cell–directed therapy for T1D. |
format | Online Article Text |
id | pubmed-3717853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-37178532014-08-01 Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes Hu, Changyun Ding, Heyuan Zhang, Xiaojun Wong, F. Susan Wen, Li Diabetes Original Research Type 1 diabetes (T1D) is a T cell–mediated autoimmune disease, although B cells also play an important role in T1D development. Both T cell– and B cell–directed immunotherapies have shown efficacy in the prevention and reversal of T1D. However, whether the combined strategy of targeting both T and B cells could further improve therapeutic efficacy remains to be explored. We show that combined treatment with intravenous antihuman CD20 (hCD20) and oral anti-CD3 significantly delays diabetes development in prediabetic hCD20 transgenic NOD mice. More importantly, the combined treatment reverses diabetes in >60% of mice newly diagnosed with diabetes. Further mechanistic studies demonstrated that the addition of oral anti-CD3 to the B-cell depletion therapy synergistically enhances the suppressive function of regulatory T cells. Of note, the oral anti-CD3 treatment induced a fraction of interleukin (IL)-10–producing CD4 T cells in the small intestine through IL-10– and IL-27–producing dendritic cells. Thus, the findings demonstrate that combining anti-CD20 and oral anti-CD3 is superior to anti-CD20 monotherapy for restoring normoglycemia in diabetic NOD mice, providing important preclinical evidence for the optimization of B cell–directed therapy for T1D. American Diabetes Association 2013-08 2013-07-17 /pmc/articles/PMC3717853/ /pubmed/23447122 http://dx.doi.org/10.2337/db12-1175 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Hu, Changyun Ding, Heyuan Zhang, Xiaojun Wong, F. Susan Wen, Li Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title | Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title_full | Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title_fullStr | Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title_full_unstemmed | Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title_short | Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes |
title_sort | combination treatment with anti-cd20 and oral anti-cd3 prevents and reverses autoimmune diabetes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717853/ https://www.ncbi.nlm.nih.gov/pubmed/23447122 http://dx.doi.org/10.2337/db12-1175 |
work_keys_str_mv | AT huchangyun combinationtreatmentwithanticd20andoralanticd3preventsandreversesautoimmunediabetes AT dingheyuan combinationtreatmentwithanticd20andoralanticd3preventsandreversesautoimmunediabetes AT zhangxiaojun combinationtreatmentwithanticd20andoralanticd3preventsandreversesautoimmunediabetes AT wongfsusan combinationtreatmentwithanticd20andoralanticd3preventsandreversesautoimmunediabetes AT wenli combinationtreatmentwithanticd20andoralanticd3preventsandreversesautoimmunediabetes |